ArticleJournal of medical biochemistry2026
Risk prognosis correlation of insulin-like growth factor binding protein-3 and insulin-like growth factor-1 in uterine fibroids.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the relationships between the levels of serum insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor 1 (IGF-1) and immune factors, as well as the prognosis of patients with uterine fibroids. Methods: The study group consisted of 186 patients with uterine fibroids who had laparoscopic myomectomy between June 2023 and June 2024, whereas the control group consisted of 208 healthy women who had physical tests over the same time period. The patients in the study group were divided into a good prognosis group (84 patients) and a poor prognosis group (92 patients). The levels of GFBP-3, IGF-1 and immune factors in the study group and the control group, and their relationships with prognosis were analysed. Results: Ten patients left the study group, and eight left the control group. IGFBP-3 and IGF-1 in the study group were (3 03.18± 42.39) mg/L and (1377.11 ± 84.78) mg/L, which both outperformed those in the control contingent [(231.2 5 ± 3 4 .1 8) mg/L and (4 3 8 .0 9 ± 5 2 .1 5) mg/L] (t= 12.87, 19.63) P< 0.001). Whereas the levels of CD3+, CD 4+, and CD 4+/CD 8+ were lower than those in the control group (t= 7.92, 8.41, 5.21, P< 0.001). Both values were higher [(284.63± 36.19) mg/L and (4 34.91± 53.28) mg/L]. P<0.001 (t= 5.96, 64.19). While the numbers of CD 3+, CD 4+, and CD 4+/CD 8+ cells were lower than those in the good prognosis group (t= 5.31, 7.03, 3.15). There was a positive correlation between CD8+ status and IGFBP-3, as well as history of uterine fibroids, number of fibroids, history of miscarriage, and duration of breastfeeding (r= 0.593, 0.452, 0.446, 0.419, 0.422, respectively). IGF-1 was negatively correlated with CD 3+, CD 4+, and CD 4+/CD 8+ (r=-0.720, -0.751, and -0.712, respectively). IGF-1 was positively correlated with CD8+ status, history of uterine fibroids, number of fibroids, history of miscarriage, and duration of breastfeeding (r= 0.631, 0.503, 0.444, 0.501, 0.451). The number of fibroids, a history of miscarriage, and the length of breastfeeding were risk variables that impacted the prognosis of patients with uterine fibroids. Conclusions: The levels of IGFBP-3, IGF-1 and CD-8+ in patients with uterine fibroids are relatively high. Moreover, IGFBP-3 and IGF-1 are related to immune factors and patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.